JP2024516621A - イヌ細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対するイヌモノクローナル抗体 - Google Patents

イヌ細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対するイヌモノクローナル抗体 Download PDF

Info

Publication number
JP2024516621A
JP2024516621A JP2023565183A JP2023565183A JP2024516621A JP 2024516621 A JP2024516621 A JP 2024516621A JP 2023565183 A JP2023565183 A JP 2023565183A JP 2023565183 A JP2023565183 A JP 2023565183A JP 2024516621 A JP2024516621 A JP 2024516621A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516621A5 (https=
Inventor
ニコラ ジェイ． メイソン
ドナルド エル． シーゲル
ニコラス チェスター
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ベチジェニックス リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ベチジェニックス リミテッド ライアビリティ カンパニー filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2024516621A publication Critical patent/JP2024516621A/ja
Publication of JP2024516621A5 publication Critical patent/JP2024516621A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023565183A 2021-04-21 2022-04-20 イヌ細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対するイヌモノクローナル抗体 Pending JP2024516621A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177692P 2021-04-21 2021-04-21
US63/177,692 2021-04-21
PCT/US2022/025614 WO2022226102A1 (en) 2021-04-21 2022-04-20 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)

Publications (2)

Publication Number Publication Date
JP2024516621A true JP2024516621A (ja) 2024-04-16
JP2024516621A5 JP2024516621A5 (https=) 2025-04-08

Family

ID=83723402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565183A Pending JP2024516621A (ja) 2021-04-21 2022-04-20 イヌ細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対するイヌモノクローナル抗体

Country Status (5)

Country Link
US (2) US12110331B2 (https=)
EP (1) EP4326324A4 (https=)
JP (1) JP2024516621A (https=)
CA (1) CA3216131A1 (https=)
WO (1) WO2022226102A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3216131A1 (en) * 2021-04-21 2022-10-27 Nicola J. MASON Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)
US20240358834A1 (en) * 2023-04-28 2024-10-31 The Trustees Of The University Of Pennsylvania Novel cd19-targeting polypeptides and cd19-directed immunotherapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040181039A1 (en) * 2001-12-21 2004-09-16 Krah Eugene Regis Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
WO2021009187A1 (en) * 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA314534A (en) * 1931-08-25 The United States Gypsum Company Roof or floor
CA3216131A1 (en) * 2021-04-21 2022-10-27 Nicola J. MASON Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040181039A1 (en) * 2001-12-21 2004-09-16 Krah Eugene Regis Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
WO2021009187A1 (en) * 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4

Also Published As

Publication number Publication date
WO2022226102A1 (en) 2022-10-27
CA3216131A1 (en) 2022-10-27
EP4326324A1 (en) 2024-02-28
US20240109967A1 (en) 2024-04-04
US20250171541A1 (en) 2025-05-29
US12110331B2 (en) 2024-10-08
EP4326324A4 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
JP7407841B2 (ja) クローディン１８ａ２に対する抗体及びその応用
CN114761036B (zh) 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
CN114805582B (zh) 抗Trop2纳米抗体及其用途
JP7766870B2 (ja) 拮抗的抗原結合タンパク質
US20250171541A1 (en) Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)
CN116496396B (zh) 抗cd70纳米抗体及其用途
US20250051447A1 (en) Fully canine anti-canine pd-1 antibodies and uses thereof
JP2021526013A (ja) 抗ヒトｌａｇ−３モノクローナル抗体とその応用
TW202307003A (zh) 抗ｃｅａ和抗ｃｄ１３７多特異性抗體及其使用方法
WO2023241493A1 (zh) 一种特异性结合Trop2的抗体或其抗原结合片段及其制备方法和应用
WO2023241492A1 (zh) 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
WO2025113570A1 (en) Fully canine antibodies and uses thereof
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
CN117460745A (zh) 抗gpc3和抗cd137多特异性抗体及使用方法
HK40071804A (zh) 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
CN121378490A (zh) Trop2抗体或其抗原结合片段及其应用
CN117186235A (zh) 抗4-1BB/抗EGFRvⅢ的双特异抗体及其制备方法和应用
OA19053A (en) Humanized anti-basigin antibodies and the use thereof.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20260312

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260415